Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)
Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)

Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)

Clinicaltrials.gov identifier:
NCT04191135


Study Contact Information:

For additional information, please contact:

Toll Free Number: 1-888-577-8839 or email: Trialsites@merck.com


Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)

About the Study

This study will look at how people with advanced () respond to different combinations of drugs. The study will look at two different treatment periods:

  • Initial period: during this initial study period, participants will receive a combination of chemotherapy and drugs. Participants with stable cancer or an improvement will be able to continue to the next part of the study.
  • Followup period: Continuing participants will be assigned to one of two groups. One group will receive the same drug combination during the followup period. The second group will instead  plus a type of known as a during the follow-up period.  

NOTE: This study is no longer enrolling patients. 

This Study is Open To:

NOTE: This study is no longer enrolling patients. 

This Study is Not Open To: